What it is:

​

Spravato is an FDA-approved treatment for adults with treatment-resistant depression and for those experiencing active suicidal thoughts or behaviors.

​

How it works:

​

Spravato is a nasal spray form of esketamine, a medication derived from ketamine. Unlike traditional antidepressants that work on serotonin or norepinephrine, Spravato acts on the brain’s NMDA receptors, rapidly increasing levels of glutamate to promote new neural connections. This unique action can relieve depressive symptoms within hours to days, rather than weeks.

 

What makes it different from other treatments:

 

Works quickly, often within the first few sessions Helps patients who have not responded to multiple antidepressants Administered under medical supervision in a safe, supportive setting Specifically approved for treatment-resistant depression and suicidal ideation

 

Who is the ideal client:

 

Spravato is designed for adults who: Have severe, treatment-resistant depression that has not improved with other medications Are experiencing suicidal ideation and need rapid, effective relief Require a new option beyond standard antidepressants and psychotherapy